



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Methods: This international, prospective cohort study enrolled patients with 15 cancer types who had a decision for surgery during the COVID-19 pandemic up to 31st August 2020. Average national Oxford COVID-19 Stringency Index scores were calculated for each patient during the period they were awaiting surgery, classified into light restrictions (index <20), moderate lockdowns (20-60), and full lockdowns (>60). The primary outcome was the non-operation rate (proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation.

Results: From 20,006 patients (466 hospitals, 61 countries), 9.1% did not receive surgery after a minimum of 3-months' follow up (median:23 weeks, IQR:16 to 30 weeks). Light restrictions were associated with a 0.6% non-operation rate, moderate lockdowns 5.5% (adjusted hazard ratio:0.81, 95% confidence interval 0.77-0.84, $p<0.001$), and full lockdowns with a 15.0% rate (HR:0.51, 0.50-0.53). In sensitivity analyses, this effect was independent of local SARS-CoV-2 rates. Each additional week in lockdown led to a 9% reduction in the likelihood in a patient undergoing their cancer operation. Frail patients, those with advanced cancer, and those in lower-income settings were particularly vulnerable to lockdown effects. Surgery beyond 12-weeks from diagnosis increased during lockdowns (9.1% in light restrictions, 10.4% moderate lockdowns, 23.8% full lockdowns).

Conclusions: Cancer surgery systems worldwide were fragile to lockdowns, with one in seven patients not undergoing planned surgery and more preoperative delays. During current and future periods of societal restriction, the resilience of elective surgery systems requires strengthening, which may include ring-fenced surgical units and critical care capacity.

Clinical trial identification: NCT04384926.

Legal entity responsible for the study: COVIDSurg Collaborate, University of Birmingham, UK.

Funding: National Institute for Health Research (NIHR) Global Health Research Unit, the Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, Medtronic, NIHR Academy, Sarcoma UK, The Urology Foundation, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.

Disclosure: All authors have declared no conflicts of interest.

<https://doi.org/10.1016/j.annonc.2021.08.1599>

1567MO

COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)

E. Romano¹, S. Gennatas², J. Rogado³, M. Sekacheva⁴, D. Viñal⁵, R. Lee⁶, A.-E. Croitoru⁷, M. Vitorino⁸, S.M. Khalaf⁹, S. Susnjar¹⁰, S. Widyanti¹¹, A. Cardena¹², M. Djerouni¹³, M. Rossi¹⁴, D. Arnold¹⁵, L. Castelo-Branco¹⁶, K.J. Harrington¹⁷, O.A. Michielin¹⁸, G. Pentheroudakis¹⁹, S. Peters¹⁸

¹Medical Oncology Department, Institut Curie, Paris, France; ²Medical Oncology Department, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, UK; ³Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain; ⁴Medical Oncology Department, Personalized Oncology Institute, Sechenov University, Moscow, Russian Federation; ⁵Medical Oncology, Hospital Universitario La Paz, Madrid, Spain; ⁶Medical Oncology, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK; ⁷Medical Oncology Department, Fundeni Clinical Institute, Bucharest, Romania; ⁸Servico Oncologia, Hospital Prof. Dr Fernando Fonseca EPE (Hospital Amadora/Sintra), Amadora, Portugal; ⁹Medical Oncology Department, SECI - South Egypt Cancer Institute - Assiut University, Assiut, Egypt; ¹⁰Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; ¹¹Department of Surgery, Oncology Division, Sebelas Maret University, Surakarta, Indonesia; ¹²Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain; ¹³Oncology Department, Dr Saadane hospital, Biskra, Algeria; ¹⁴Oncology, ASO "SS. Antonio, Biagio e Cesare Arrigo", Alessandria, Italy; ¹⁵Oncology, Haematology, Palliative Care Dept., Asklepios Klinik Altona - Asklepios Kliniken, Hamburg, Germany; ¹⁶Medical Oncology Department, Hospital Distrital de Faro, Faro, Portugal; ¹⁷Division of Radiotherapy and Imaging, The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, UK; ¹⁸Oncology Department, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, Switzerland; ¹⁹Scientific and Medical Division, ESMO - European Society for Medical Oncology, Lugano, Switzerland

Background: At the height of the first wave of the SARS-CoV-2 pandemic, ESMO mobilized to accelerate research for the understanding of COVID-19 in cancer patients (pts). ESMO CoCARE is an international collaborative registry-based, cohort study, gathering real-world data and information from healthcare professionals about the natural history, treatment and outcomes of COVID-19 in cancer pts.

Methods: ESMO CoCARE captures information on pts with any solid or hematologic malignancy (including cancer survivors free of disease for ≥ 5 years) presenting with a COVID-19 diagnosis in any of the participating centers. Data collected since 06/2020 include demographics, cancer characteristics and status, co-morbidities, COVID-19 clinical features, course, management and outcome. Factors influencing COVID-19 severity (hospitalization +/- ICU support needed) and recovery are investigated using

multivariable logistic regression with backward elimination method. The study is ongoing.

Results: The current analysis includes 1551 registered pts (19 countries; 87% pts from 23 European centers, 7% and 6% pts from 5 Northern African and 7 Asian centers), with COVID-19 diagnosis as of 11/03/2021. Median age was 64 years, with the majority female (52%), cancer stage III/IV (58%), and on active cancer treatment (60%). 65% had severe COVID-19 requiring hospitalization, with 11% receiving intensive care. In multivariable analysis, in addition to demographics (male gender, older age, other ethnicity than Caucasian, lower BMI), co-morbidities and symptomatic COVID-19, severe disease was associated to higher ECG PS (Odds Ratio (OR)_{2 vs 0}=5.9, OR_{1 vs 0}=2.1), hematological malignancies (OR_{hemvs solid}=2.0), and active/progressive cancer status (OR_{progressives no evidence of disease}=1.6). 98% of pts with mild disease recovered, as opposed to only 70% of those with severe disease. Cancer stage was an additional prognostic factor for recovery (OR_{I/II vs IV}=3.4).

Conclusions: Demographic characteristics, type and status of cancer, and symptomatology of COVID-19 increase the probability of severe disease, while advanced cancer stage is also associated with the risk of death.

Legal entity responsible for the study: Institut Curie, Paris, France.

Funding: ESMO - European Society for Medical Oncology.

Disclosure: E. Romano: Financial Interests, Institutional, Funding, Investigator-initiated trial: AstraZeneca; Financial Interests, Institutional, Funding, Investigator-initiated trial: BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pierre Fabre. R. Lee: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Funding: BMS. A. Croitoru: Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Astellas; Financial Interests, Personal and Institutional, Funding: Bristol-Myers Squibb; Financial Interests, Personal and Institutional, Funding: Merck; Financial Interests, Personal and Institutional, Funding: Astellas; Financial Interests, Personal and Institutional, Funding: Servier; Financial Interests, Personal and Institutional, Funding: Five Prime Therapeutics; Financial Interests, Personal and Institutional, Funding: Amgen; Financial Interests, Personal, Other, Travel funding: Merck; Financial Interests, Personal, Other, travel funding: Servier; Financial Interests, Personal, Other, travel funding: Roche. S. Susnjar: Financial Interests, Personal, Other, Honoraria and/or advisory fees: Roche; Financial Interests, Personal, Other, Honoraria and/or advisory fees: Pfizer; Financial Interests, Personal, Other, Honoraria and/or advisory fees: Novartis; Financial Interests, Personal, Other, Honoraria and/or advisory fees: AstraZeneca; Financial Interests, Personal, Other, Honoraria and/or advisory fees: Amicus. M. Rossi: Financial Interests, Personal, Other, travel and personal fees: Novartis; Financial Interests, Personal, Other, travel and personal fees: Ipsen. O.A. Michielin: Financial Interests, Personal, Other, personal fees: Bristol-Myers Squibb; Financial Interests, Personal, Other, personal fees: MSD; Financial Interests, Personal, Other, personal fees: Novartis; Financial Interests, Personal, Other, personal fees: Roche; Financial Interests, Personal, Other, personal fees: Amgen; Financial Interests, Personal, Other, personal fees: NeraCare GmbH. G. Pentheroudakis: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Institutional, Principal Investigator: AbbVie; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Principal Investigator, Coordinating PI: Amgen; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Institutional, Research Grant: Boehringer Ingelheim; Financial Interests, Institutional, Funding: Boehringer Ingelheim; Financial Interests, Institutional, Funding: Bristol Myers Squibb; Financial Interests, Institutional, Principal Investigator: Bristol Myers Squibb; Financial Interests, Institutional, Principal Investigator: Debbiopharm; Financial Interests, Institutional, Funding: Enorasis; Financial Interests, Institutional, Funding: Genekor; Financial Interests, Institutional, Funding: Ipsen; Financial Interests, Institutional, Principal Investigator: Ipsen; Financial Interests, Institutional, Funding: Janssen; Financial Interests, Institutional, Principal Investigator: Lilly; Financial Interests, Institutional, Funding: Merck; Financial Interests, Institutional, Principal Investigator: Merck; Financial Interests, Institutional, Funding: MSD; Financial Interests, Institutional, Principal Investigator: MSD; Financial Interests, Institutional, Funding: Pfizer; Financial Interests, Institutional, Principal Investigator: Roche; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Funding: Sanofi; Financial Interests, Institutional, Principal Investigator, Coordinating PI: Servier; Financial Interests, Institutional, Funding: Servier. S. Peters: Consultation / Advisory role: AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Bio Invent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, F. Hoffmann-La Roche/Genentech, Foundation Medicine, Illumina, Incyte, IQVIA, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Novartis, PharmaMar, Phosphatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, Vaccibody. Talk in a company's organized public event: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, e-cancer, Eli Lilly, F. Hoffmann-La Roche/Genentech, Illumina, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, RTP, Sanofi, Takeda. Receipt of grants/research supports: (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche/Genentech, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, and Pfizer, Phosphatin Therapeutics. All other authors have declared no conflicts of interest.

<https://doi.org/10.1016/j.annonc.2021.08.1560>

1568P

Clinical and laboratory outcomes of solid cancer patients reinfected with SARS-CoV-2

O. Yazici¹, O. Ünsal¹, N. Özdemir¹, E. Çubukçu², B. Ocak², A. Üner¹, A. Özet¹

¹Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey; ²Medical Oncology, Uludağ University Faculty of Medicine, Bursa, Turkey

Background: COVID-19 reinfection has been increasingly reported. Immunocompromised patients may be more susceptible to COVID-19 reinfection due to impaired immune responses to the virus. The current study aimed to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19.